MindMend’s go-to-market strategy is focused, phased, and relationship-driven. Our initial target market is Parkinson’s clinical trials managed by top-tier contract research organizations (CROs), pharmaceutical sponsors, and academic research institutions. These groups already outsource data collection tools and are actively seeking ways to improve trial efficiency and data quality.
We will begin by partnering with a select group of research organizations to run pilot studies using our device. These pilots will generate clinical validation data, user feedback, and published results to support regulatory approval and strengthen our market credibility.
Following FDA clearance, we will launch commercially with these same early adopters, organizations already familiar with our technology and invested in our success. We will use direct sales and strategic relationships, starting with six CROs that manage one-third of all Parkinson’s trials, representing an $18 million serviceable available market.
Over time, we will expand to additional trial sponsors and other neurodegenerative disease markets, leveraging our proven platform to serve broader research needs.
By starting with a narrow, high-value segment and growing through validated outcomes and strong partnerships, we are building a scalable and capital-efficient path to market.
